US Patent Issued to Inhibrx Biosciences on June 17 for "Multispecific polypeptide constructs having constrained CD3 binding and related methods and uses" (California Inventors)

ALEXANDRIA, Va., June 19 -- United States Patent no. 12,331,132, issued on June 17, was assigned to Inhibrx Biosciences Inc. (La Jolla, Calif.).

"Multispecific polypeptide constructs having constrained CD3 binding and related methods and uses" was invented by Brendan P. Eckelman (La Jolla, Calif.), Michael D. Kaplan (La Jolla, Calif.), Katelyn M. Willis (La Jolla, Calif.) and John C. Timmer (La Jolla, Calif.).

According to the abstract* released by the U.S. Patent & Trademark Office: "The invention relates generally to multispecific polypeptides having constrained CD3 binding. In some embodiments, components of the multispecific polypeptides are connected by a non-cleavable linker. Also provided are methods of making and using these multi...